We are live on ! Find out more
HF

HRT Financial Portfolio holdings

AUM $40.1B
1-Year Est. Return 58.22%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
+58.22%
3 Year Est. Return
+133.11%
5 Year Est. Return
+158.39%
10 Year Est. Return
+582.81%
AUM
$9.25B
AUM Growth
+$131M
Cap. Flow
+$656M
Cap. Flow %
7.09%
Top 10 Hldgs %
27.25%
Holding
3,916
New
1,066
Increased
554
Reduced
539
Closed
1,190

Top Buys

Rank Stock Value
1
DRE
Duke Realty Corp.
DRE
+$260M
2
CVX icon
Chevron
CVX
+$144M
3
TEAM icon
Atlassian
TEAM
+$127M
4
OXY icon
Occidental Petroleum
OXY
+$122M
5
SNPS icon
Synopsys
SNPS
+$118M

Sector Composition

Rank Sector Weight
1 Technology 15.1%
2 Financials 9.62%
3 Energy 5.36%
4 Consumer Discretionary 5.16%
5 Healthcare 5.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DOMA
3751
DELISTED
Doma Holdings, Inc.
DOMA
-18,680
Closed -$481K
RXDX
3752
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
-45,967
Closed -$1.3M
RUTH
3753
DELISTED
Ruth's Hospitality Group, Inc.
RUTH
-16,143
Closed -$262K
ATIP.WS
3754
DELISTED
ATI Physical Therapy, Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
ATIP.WS
$0 ﹤0.01%
10,348
DBD
3755
DELISTED
Diebold Nixdorf Incorporated
DBD
-140,043
Closed -$317K
ACOR
3756
DELISTED
Acorda Therapeutics
ACOR
-1,966
Closed -$18K
KBAL
3757
DELISTED
Kimball International
KBAL
-38,603
Closed -$296K
QTEKW
3758
DELISTED
QualTek Services Inc. Warrant
QTEKW
-13,212
Closed -$2K
CYAD
3759
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
-33,288
Closed -$57K
JNCE
3760
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
-20,010
Closed -$60K
BBBY
3761
DELISTED
Bed Bath & Beyond Inc
BBBY
-263,293
Closed -$1.31M
PRVB
3762
DELISTED
Provention Bio, Inc. Common Stock
PRVB
-45,043
Closed -$180K
ML
3763
DELISTED
MoneyLion Inc.
ML
-8,317
Closed -$329K
ATCX
3764
DELISTED
Atlas Technical Consultants, Inc. Class A Common Stock
ATCX
-12,748
Closed -$67K
PEARW
3765
DELISTED
Pear Therapeutics, Inc. Warrant
PEARW
-16,778
Closed -$2K
PEAR
3766
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
-201,829
Closed -$310K
VORB
3767
DELISTED
Virgin Orbit Holdings, Inc. Common Stock
VORB
-46,794
Closed -$179K
PLXP
3768
DELISTED
PLx Pharma Inc. Common Stock
PLXP
-14,795
Closed -$35K
APEN
3769
DELISTED
Apollo Endosurgery, Inc.
APEN
-18,538
Closed -$67K
VLTA
3770
DELISTED
Volta Inc.
VLTA
-208,958
Closed -$271K
NOGN
3771
DELISTED
Nogin, Inc. Common Stock
NOGN
-2,505
Closed -$500K
ATCO
3772
DELISTED
Atlas Corp.
ATCO
-84,399
Closed -$903K
EVOP
3773
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
-10,151
Closed -$238K
CUEN
3774
DELISTED
Cuentas Inc. Common Stock
CUEN
-1,094
Closed -$8K
IAA
3775
DELISTED
IAA, Inc. Common Stock
IAA
-16,209
Closed -$531K

Similar funds

HRT Financial's Q3 2022 Portfolio in Review

As of Q3 2022, HRT Financial held 3,916 positions worth $9.25B, up 1.4% from $9.12B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HRT Financial deployed $656M of net new capital in Q3 2022, opening 1,066 new positions and adding to 554 existing holdings. Its largest new stake was Duke Realty Corp.: 4,434,270 shares worth $214M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 10% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was iShares Russell 2000 ETF, an estimated $225M trimmed.

  • HRT Financial's largest Q3 2022 buy was Duke Realty Corp.: 4,434,270 shares worth $214M.
  • HRT Financial added most to Atlassian in Q3 2022, an estimated $127M increase.
  • HRT Financial's biggest Q3 2022 reduction was iShares Russell 2000 ETF, cutting an estimated $225M.
  • HRT Financial fully exited Pioneer Natural Resource Co. in Q3 2022, selling an estimated $120M.
  • HRT Financial's ten largest holdings make up 27% of its $9.25B portfolio in Q3 2022.
  • HRT Financial opened 1,066 new positions and closed 1,190 in Q3 2022.
  • HRT Financial's portfolio value rose 1.4% quarter-over-quarter to $9.25B.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.